Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Booms, Busts, and Recoveries -- Ignore unavailable to you. Want to Upgrade?

To: elmatador who wrote (66081)	7/10/2005 3:36:29 PM
From: energyplay	Read Replies (1) \| Respond to of 74559

Re: Abbot Labs and Brazil - "Throughout this process, we were mindful of the importance of the outcome of this issue, which has implications beyond our company and our industry for all innovators," Brotz added." That's a pretty clear admission that they were pressured, maybe by other firms, maybe by the US government. My guess is Brazil claims a victory, but doesn't do too much to follow on other drugs - maybe another one or two visible "fights" for getting lower prices, where the outcome is more or less known in advance. More 'wins' for Lula.... So what does the US get out of this ? Open access to own develop Brazilian farm land ? Or some other things ? Remember, Embarder may get to build the airframe for the next US Navy anti-submarine aircraft.... Aircraft have large fixed costs, then a downward sloping cost per each additional because of cost spreading and a learning curve, introduction of competitive sources with volume, etc. The US Navy order can turn a successful product into a real gravy train / cash cow which will run for years. The big drug companies will wait for another opportunity to fight the patent grab, probably with a country with less technical capability, or a country the US State Department doesn't like as much ..... ;-)